Accelerating compliance
and approvals with unmatched regulatory insight and experience.

Contact Us Today
The Lachman Difference

The most efficient services.
The most qualified professionals.

Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA consultants and industry experts has offered compliance, regulatory affairs, and science & technology services to clients around the world.

Learn More About Us

Stay in the know

Sign up today for the Lachman Consultants blog.

Get the latest news on industry compliance, regulatory affairs, technical services, and a whole lot more.

    AREAS SERVED BY LACHMAN CONSULTANTS

    ADVANCE. CONFIDENTLY.

    As long-standing leaders in technical and regulatory consulting services, Lachman Consultants provides both experience and excellence through an unmatched team of respected industry professionals and SMEs.

    Mock FDA Audits

    Are you fully prepared for an inspection at your facility?

    Our team of experienced ex-FDA investigators offer comprehensive Mock FDA Audit services to help you prepare for an actual FDA inspection. Our team of experts will conduct a thorough inspection of your facility, review your documentation, and provide you with valuable feedback on areas that need improvement to ensure compliance with FDA regulations – both remotely and on-site.

    Learn More About Mock FDA Audits

    OnCall Image

    Recent Posts

    The Lachman Consultants Blog

    The latest on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Q&A Guidance on Mandatory Cosmetic Recall Provisions

    At the end of December 2022, “the President signed into law the Cons...
    Read More

    Clearing Up Some Confusion Around Establishment Registrations

    FDA requires registration of facilities for everything from animal/vet...
    Read More

    One in Three New Prescriptions Are Never Filled

    The fact that 33% of prescriptions not filled is a staggering figure a...
    Read More

    There is the Comparability Protocol for Drugs, and There is the Predetermined Change Control Plan for Devices

    The CDER and CBER call a prospective written plan to assess and manage...
    Read More

    OGD Announces GDUFA Science and Research Priority Initiatives

    Yesterday, the FDA provided the 2027 science and research initiatives ...
    Read More
    person looking at phone with prescription

    When the App Affects the Dose: Labeling, Data, and Software

    The newly released FDA Guidance “Regulatory Considerations for Presc...
    Read More
    ADVANCE CONFIDENTLY
    Contact Us Today